This article has Open Peer Review reports available.
Outpatient costs in pharmaceutically treated diabetes patients with and without a diagnosis of depression in a Dutch primary care setting
© Bosmans and Adriaanse; licensee BioMed Central Ltd. 2012
Received: 4 July 2011
Accepted: 23 February 2012
Published: 23 February 2012
To assess differences in outpatient costs among pharmaceutically treated diabetes patients with and without a diagnosis of depression in a Dutch primary care setting.
A retrospective case control study over 3 years (2002-2004). Data on 7128 depressed patients and 23772 non-depressed matched controls were available from the electronic medical record system of 20 general practices organized in one large primary care organization in the Netherlands. A total of 393 depressed patients with diabetes and 494 non-depressed patients with diabetes were identified in these records. The data that were extracted from the medical record system concerned only outpatient costs, which included GP care, referrals, and medication.
Mean total outpatient costs per year in depressed diabetes patients were €1039 (SD 743) in the period 2002-2004, which was more than two times as high as in non-depressed diabetes patients (€492, SD 434). After correction for age, sex, type of insurance, diabetes treatment, and comorbidity, the difference in total annual costs between depressed and non-depressed diabetes patients changed from €408 (uncorrected) to €463 (corrected) in multilevel analyses. Correction for comorbidity had the largest impact on the difference in costs between both groups.
Outpatient costs in depressed patients with diabetes are substantially higher than in non-depressed patients with diabetes even after adjusting for confounders. Future research should investigate whether effective treatment of depression among diabetes patients can reduce health care costs in the long term.
Depression is common in primary care with prevalence rates ranging from 5% to 10%  and has a substantial impact on quality of life and societal costs [2, 3]. In people with diabetes increased depression rates are found in comparison with people without diabetes .
Depression in combination with diabetes as compared with diabetes alone, has been linked with poor self-care and adherence to medical treatment, poorer glycemic control, more diabetes complications, and a higher risk of morbidity and all cause mortality . Moreover, comorbid depression and diabetes is associated with increased health care costs in comparison with diabetes alone [9, 10].
Most depressed patients and diabetes patients are treated in primary care. In a recent retrospective study, we showed that diabetes was almost 3 times as prevalent in treated depressed patients than in matched controls in primary care . Since both the numbers of patients with depression and of patients with diabetes are increasing rapidly worldwide and both conditions are associated with raised health care costs, it is important to examine the relation between depression, diabetes and costs.
Several studies determined the prevalence of depression in diabetes populations and subsequently evaluated costs [9, 10]. In a large USA sample of adult health plan members with diabetes, depression was associated with 50-75% increase in health services use . In a primary-care-based sample of patients with type 1 and 2 diabetes, higher levels of depressive symptom severity were associated with increased health care costs compared with patients with low-severity depressive symptoms . Whereas the majority of other studies assessed the presence of depressive symptoms using questionnaires in a diabetes population, our study is unique in the sense that it was done in a very large primary care database using selection criteria based on objective information registered by the GP. The aim of the study was to compare differences in resource use and health care costs between pharmaceutically treated diabetes patients with and without depression who were identified in a primary care cohort from the Netherlands while correcting for age, sex and comorbidity.
This was a retrospective case control study over 3 years (2002-2004). In a cohort of depressed patients and their non-depressed matched controls diabetes patients were identified. The objective of this study was to investigate differences in outpatient costs between pharmaceutically treated diabetes patients with and without depression.
The study has been conducted according to the principles expressed in the Declaration of Helsinki. The study was approved by the scientific council of the Primary Health Care Organisation Almere. The data were analyzed anonymously. Therefore, no ethical approval was necessary for this project.
Data were retrieved from electronic medical records kept by 20 general practices organized in one large primary care organization in Almere. Almere is a municipality in the centre region of the Netherlands with approximately 184,400 citizens (7 July 2008). All primary care practices and pharmacies in Almere are organized in one central health organization and share the same electronic medical record system saved in one central database. Data in this system include information on consultations, diagnoses, referrals and prescriptions. Diagnoses are recorded using the ICPC-2 coding system (International Classification of Primary Care). Drugs are classified according to the Anatomical Therapeutic Chemical (ATC) classification system. In the ATC classification system which is maintained by the WHO, the active substances of drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutic properties.
The Dutch health care system is based on the principle that everybody has adequate access to health care. Almost everyone in The Netherlands is registered with a general practitioner. Until 2006 two forms of insurance existed in The Netherlands: private and social insurance. People with earnings above approximately €30,000 per year and their dependants were excluded from statutory coverage provided by public sickness funds and could purchase coverage from private health insurers.
Subsequently, in this population of 30,900 primary care patients diabetes patients were identified. Patients were classified as having diabetes when they received pharmaceutical treatment consisting of insulin (ATC code A10A) and/or oral blood glucose lowering drugs (ATC code A10B). In this study sample, a diagnosis of diabetes was based on medication data and not on diagnostic codes. Medication data rather than problem lists were used, because problem lists (a list of clinically relevant, current health problems of the patient coded using the ICPC-2) may not be reliable and/or up to date. This means that it was not possible to discriminate between diabetes mellitus types 1 and 2 and that patients treated by lifestyle advices only are not included. A total of 393 (5.5%) depressed patients with diabetes was identified and 494 (2.1%) non-depressed patients with diabetes resulting in 1 to 2 non-depressed patients per depressed patient.
To define co morbidity a Dutch adaptation  of the revised chronic disease score (CDS) was used . The CDS is a measure of chronic disease status and uses ATC codes from automated pharmacy data as an indicator for the presence of certain chronic conditions. The following 25 conditions are distinguished: coronary and peripheral vascular disease, epilepsy, hypertension, HIV/AIDS, tuberculosis, rheumatologic conditions, hyperlipidemia, malignancies, Parkinson's disease, renal disease (including end stage renal disease), cardiac disease/arteriosclerotic cardiovascular disease/congestive heart failure, diabetes, glaucoma, peptic acid disease, cystic fybrosis, transplantations, respiratory illness/asthma, thyroid disorders, gout, Crohn's and ulcerative colitis, pain and inflammation, pain, depression, psychotic illness (including bipolar disorders), anxiety and tension. Diabetes and depression were excluded from the analyses concerning comorbidity.
Health care utilization
Mean number of contacts and unit costs in Euros for the year 2003.
Number of contacts
Unit cost (€, 2003)
Contacts with the GP
Consultation, long duration*
Home visit, long duration*
11.0 or 13.1
Mental health care
Regional institute for mental
dependent on drug & dose
Costs were calculated using Dutch guidelines for cost studies. If available, Dutch standard costs were used to value health care utilization [21, 22]. Otherwise, prices from health care providers themselves, prices from professional organizations or tariffs were used. Medication costs were estimated using prices from the pharmacy database of the Royal Dutch Society for Pharmacy . For drugs of which 300 units or more were delivered the specific price was obtained from the pharmacy database. For all other drugs the median of the obtained drug prices, which was to €0.19 per unit, was used. All prices were adjusted to the year 2003 using consumer price indices . Table 1 lists the unit costs used in this cost-of-illness study.
In all analyses depressed patients with diabetes were compared with non-depressed patients with diabetes. Healthcare utilization was dichotomized according to whether a patient visited a specific provider yes or no. These rates were compared using logistic binary regression while correcting for age and sex. Costs generally have a highly skewed distribution caused by many patients with low costs and few patients with high costs . Therefore, bias-corrected and accelerated bootstrapping with 1000 replications was used to compare costs between the two groups . Bootstrapping was performed using StataSE 10 for Windows (Stata Corp LP, USA).
Patients in this study were clustered within GPs. It is reasonable to assume that patients between GPs differ in some characteristics, for example personality characteristics of the GP. Multilevel modelling is a statistical technique that can be used to correct for this clustering. The clustering in this study was modest (ICC 0.06), but we still decided to correct for clustering. Therefore, a random intercept was added to the multilevel models with group (depressed or non-depressed) as the central determinant to correct for clustering of patients within GPs. Total costs were adjusted for potential confounding by age, sex, type of insurance and medical comorbidity in the multilevel analyses to be able to estimate the effect of being depressed on outpatient costs among diabetes patients as unbiased as possible. All conditions distinguished by the CDS except depression and diabetes were included in the model as being present or not. In 2002-2004 patients could have private or social insurance. Private insurance indicates a higher socioeconomic status. Therefore, type of insurance was also included. The multilevel models were subsequently bootstrapped (1000 replications) and bias-corrected and accelerated confidence intervals were estimated. The multilevel analyses and bootstrapping were performed in StataSE 10 for Windows (Stata Corp LP, USA).
Study sample characteristics, diabetes regimen and co morbidity of depressed patients with diabetes versus non-depressed patients with diabetes.
Depressed (n = 393)
Non-depressed (n = 494)
% Female (n)
Mental health treatment
No mental health treatment
Referral to a psychiatric care provider
Antidepressants + referral
Oral glucose medication
Oral glucose medication + insulin
0 comorbid conditions
1-2 comorbid conditions
More than 3 comorbid conditions
Health care utilization
Mean (SD) health care utilization per patient during 3 years (2002-2004) in depressed patients with diabetes and non-depressed patients with diabetes.
Depressed (n = 393)
Non-depressed (n = 494)
Contacts with the GP
Mental health care
Regional institute for mental
Mean (SD) annual costs (unadjusted) in depressed patients with diabetes and non- depressed patients with diabetes.
Unadjusted (95% CI)
122 (97; 145)
103 (81; 129)
34 (17; 55)
33 (14; 53)
35 (16; 55)
34 (16; 55)
Mental health care
174 (134; 224)
194 (151; 247)
30 (19; 41)
31 (21; 42)
152 (125; 182)
157 (129; 186)
547 (466; 635)
553 (468; 641)
Results of multilevel analyses incorporating a random intercept for clustering of patients within general practitioners.
Only group included
Crude model + age, sex
Model 1 + type of insurance
Model 2 + diabetes treatment
Model 3 + comorbidity1
Model 3 + comorbidity in three categories2
In this study we identified diabetes patients in a primary care cohort consisting of treated depressed patients and non-depressed matched controls. We found that total costs in depressed patients with diabetes were twice as high as in non-depressed patients with diabetes in the Netherlands. Even after correction for age, sex, type of insurance, diabetes treatment, and comorbid conditions total annual costs in depressed patients were €463 higher than in non-depressed patients, which was statistically significant. Adjustment for comorbidity had the largest impact on the difference in costs between the two groups.
Consistent with previous research, our results show that depression comorbid with diabetes was associated with significantly higher health care costs than diabetes alone and that this increase was mainly the result of increased general medical care and not mental health care utilization [9, 10]. Our study is different from these studies in the sense that we identified diabetes patients in a large cohort of depressed primary care patients and their matched controls, while these other studies assessed the presence of depression using questionnaires in participants sampled from a diabetes registry. The observed increase in health care costs in depressed patients with diabetes may be caused by unobserved differences in severity of diabetes or other comorbid chronic conditions . However, even after we corrected for comorbid conditions health care costs in depressed patients with diabetes were significantly higher than in non-depressed patients with diabetes. An alternative hypothesis is that depression may interfere with effective self-care for diabetes leading to higher health care costs  and that effective treatment may result in normalised health care costs. Recent studies evaluating the cost-effectiveness of systematic identification and treatment of depression in diabetes patients showed that such interventions may be cost-effective [27, 28]. The Pathways Study showed that a collaborative depression care program resulted in lower costs over a 5-year period compared with usual care, although this difference was not statistically significant .
The cost estimates obtained in our study are lower than in other studies [30, 31]. The most likely explanation for this difference is that, since these other studies depended on GPs for patient selection, patients with more severe diabetes were included in these studies. Other explanations may be that not all referrals were registered by the GPs in their electronic medical record system and that the national health care utilization rates may be an underestimation of the number of contacts for diabetes patients.
Strengths of this study are that we used complete records of a large cohort of depressed patients and matched controls in which we identified diabetes patients. Second, ATC codes of delivered medication were used to determine the most important covariates, i.e., diabetes, diabetes treatment and comorbidities. We expect that this information on delivered medication is very accurate, since reimbursement by insurance companies is based on the same data we used for this study. However, when interpreting these findings one should also consider some limitations. Only outpatient costs were considered in this study. However, hospitalization costs and lost productivity costs due to absenteeism, presenteeism, early retirement and mortality may be substantially larger than outpatient costs in this population. From a societal perspective, this is an important limitation. Including these costs will result in higher cost estimates, and, most likely, to a larger difference in costs between depressed and non-depressed diabetes patients. Other limitations include the following. First, it was not possible to discriminate between diabetes mellitus type 1 and type 2, because we used medication data to determine the presence of diabetes. This means that this study sample does not include diabetes patients treated by lifestyle advices only, which is likely to underestimate the true diabetes prevalence rates in both groups. Second, we only had the disposal of data on referrals and not on the number of contacts following a referral. Therefore, we had to use national health care utilization data to estimate the number of contacts patients had with other health care providers than the GP. Patients with depression and diabetes are likely to require more complex care than patients with diabetes alone. However, the magnitude of this effect is unknown. Therefore, the cost difference reported in this study is likely to be an underestimation of the true cost difference. Third, comorbidity was defined based on medication prescriptions. Thus, it is possible that patients who incidentally used one of the medications included in the CDS are incorrectly labelled as having a chronic disease. This may have overestimated the effect of comorbidity on total costs. Fourth, for our selection of depressed patients, we relied on the diagnostic accuracy and treatment by the GP. Thus, our study did not include depressed persons who do not visit their GP, depressed persons who are not recognized as being depressed by the GP and depressed persons who are recognized as being depressed by the GP but do not receive a registered diagnosis of depression or treatment for their depression. Therefore, total costs of depression among patients with diabetes are underestimated, while inclusion of depressed persons in matched controls may lead to an overestimation of mean costs in controls. Finally, diabetes patients were identified in depressed patients and non-depressed matched controls. More than one control was available for depressed patients in younger age categories. As the prevalence of diabetes increases with age and depressed patients were older than non-depressed patients as a consequence of our selection process, it is possible that the prevalence of diabetes in depressed patients is an overestimation.
In conclusion, our results show that even after adjustment for comorbid conditions health care costs in depressed patients with diabetes are significantly higher than in non-depressed patients with diabetes. More longitudinal research in usual clinical practice is needed on the costs of depression in combination with diabetes with a distinction into diabetes mellitus 1 and 2. Research should also indicate whether adequate treatment of depression among diabetes patients can lead to lower health care costs in the long term. Finally, the results are of importance to policy makers. The results of the study clearly show that the combination of diabetes and depression leads to markedly increased health care costs. Considering the expected rise in the prevalence of diabetes, funding should be made available to disentangle the relationship between diabetes and depression and to develop treatments to prevent depression in diabetes patients.
We would like to thank the Primary Health Care Organisation Almere who gave permission to use their electronic medical record data for the purposes of this study.
- Katon W, Schulberg H: Epidemiology of depression in primary care. Gen Hosp Psychiatry. 1992, 14 (4): 237-47. 10.1016/0163-8343(92)90094-Q.View ArticlePubMedGoogle Scholar
- Luppa M, Heinrich S, Angermeyer MC, Konig HH, Riedel-Heller SG: Cost-of-illness studies of depression: a systematic review. J Affect Disord. 2007, 98 (1-2): 29-43. 10.1016/j.jad.2006.07.017.View ArticlePubMedGoogle Scholar
- Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997, 349 (9063): 1436-42. 10.1016/S0140-6736(96)07495-8.View ArticlePubMedGoogle Scholar
- Ali S, Stone MA, Peters JL, Davies MJ, Khunti K: The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006, 23 (11): 1165-1173. 10.1111/j.1464-5491.2006.01943.x.View ArticlePubMedGoogle Scholar
- Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ, et al: Depression and diabetes treatment nonadherence: a meta-analysis. Diabet Care. 2008, 31 (12): 2398-2403. 10.2337/dc08-1341.View ArticleGoogle Scholar
- Lustman PJ, Anderson RJ, Freedland KE, de GM, Carney RM, Clouse RE: Depression and poor glycemic control: a meta-analytic review of the literature. Diabet Care. 2000, 23 (7): 934-942. 10.2337/diacare.23.7.934.View ArticleGoogle Scholar
- Baldwin RC, Anderson D, Black S, Evans S, Jones R, Wilson K, et al: Guideline for the management of late-life depression in primary care. Int J Geriatr Psychiatry. 2003, 18 (9): 829-838. 10.1002/gps.940.View ArticlePubMedGoogle Scholar
- Katon W, Fan MY, Unutzer J, Taylor J, Pincus H, Schoenbaum M: Depression and diabetes: a potentially lethal combination. J Gen Intern Med. 2008, 23 (10): 1571-1575. 10.1007/s11606-008-0731-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Simon GE, Katon WJ, Lin EH, Ludman E, VonKorff M, Ciechanowski P, et al: Diabetes complications and depression as predictors of health service costs. Gen Hosp Psychiatry. 2005, 27 (5): 344-351. 10.1016/j.genhosppsych.2005.04.008.View ArticlePubMedGoogle Scholar
- Ciechanowski PS, Katon WJ, Russo JE: Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 2000, 160 (21): 3278-85. 10.1001/archinte.160.21.3278.View ArticlePubMedGoogle Scholar
- Adriaanse MC, Bosmans JE: Diabetes, diabetes regimen, and co morbidity in depressed patients compared with matched controls in primary care in the Netherlands. Diabet Med. 2010, 27 (6): 718-22. 10.1111/j.1464-5491.2010.03002.x.View ArticlePubMedGoogle Scholar
- Lamers LM, van Vliet RC: The Pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation. Health Policy. 2004, 68 (1): 113-121. 10.1016/j.healthpol.2003.09.001.View ArticlePubMedGoogle Scholar
- Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE: A chronic disease score with empirically derived weights. Med Care. 1995, 33 (8): 783-795. 10.1097/00005650-199508000-00004.View ArticlePubMedGoogle Scholar
- Swinkels ICS, Leemrijse C, De Bakker D: Trendcijfers 2001-2005 Fysiotherapie [Trends 2001-2005 Physiotherapy]. 2007, Utrecht, NIVELGoogle Scholar
- Swinkels ICS, Leemrijse C, De Bakker D: Trendcijfers 2002-2005 Oefentherapie Cesar [Trends 2002-2005 Cesar exercise therapy]. 2007, Utrecht, NIVELGoogle Scholar
- Swinkels ICS, Leemrijse C, De Bakker D: Trendcijfers 2002-2005 Oefentherapie Mensendieck [Trends 2002-2005 Mensendieck exercise therapy]. 2007, Utrecht, NIVELGoogle Scholar
- Nederlands instituut voor onderzoek van de gezondheidszorg (NIVEL): Eerstelijns GGZ: Eerstelijnspsycholoog [Primary mental health care: Psychologist]. 2007Google Scholar
- Nederlands instituut voor onderzoek van de gezondheidszorg (NIVEL): Eerstelijns GGZ: Algemeen Maatschappelijk Werk [Primary mental health care: Social worker]. 2007Google Scholar
- De Vries S, Wierdsma A: Verandering in behandelduur in GGZ Rijnmond in de periode 2002-2004 [Changes in treatment duration at GGZ Rijnmond in the period 2002-2004]. 2006, O3 Onderzoekcentrum GGZ RijnmondGoogle Scholar
- Statistics Netherlands: 2007, Voorburg/Heerlen, Centraal Bureau voor de Statisti (CBS)Google Scholar
- Oostenbrink JB, Koopmanschap MA, Rutten FF: Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics. 2002, 20 (7): 443-454. 10.2165/00019053-200220070-00002.View ArticlePubMedGoogle Scholar
- Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH: Handleiding voor kostenonderzoek: Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2004 [Handbook for cost studies: methods and standard costs for economic evaluation in health care. Updated version 2004]. 2004, Den Haag, The Netherlands, College voor ZorgverzekeringenGoogle Scholar
- Z-index: G-Standaard. 2006, The Hague, The Netherlands, Z-indexGoogle Scholar
- Thompson SG, Barber JA: How should cost data in pragmatic randomised trials be analysed?. BMJ. 2000, 320 (7243): 1197-200. 10.1136/bmj.320.7243.1197.View ArticlePubMedPubMed CentralGoogle Scholar
- Efron B, Tibshirani RJ: An introduction to the bootstrap. 1993, New York: Chapman & HallView ArticleGoogle Scholar
- Ciechanowski PS, Katon WJ, Russo JE, Hirsch IB: The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Gen Hosp Psychiatry. 2003, 25 (4): 246-252. 10.1016/S0163-8343(03)00055-0.View ArticlePubMedGoogle Scholar
- Simon GE, Katon WJ, Lin EH, Rutter C, Manning WG, Von Korff M, et al: Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. Arch Gen Psychiatry. 2007, 64 (1): 65-72. 10.1001/archpsyc.64.1.65.View ArticlePubMedGoogle Scholar
- Katon W, Unutzer J, Fan MY, Williams JW, Schoenbaum M, Lin EH, et al: Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. Diabet Care. 2006, 29 (2): 265-270. 10.2337/diacare.29.02.06.dc05-1572.View ArticleGoogle Scholar
- Katon WJ, Russo JE, Von Korff M, Lin EH, Ludman E, Ciechanowski PS: Long-term effects on medical costs of improving depression outcomes in patients with depression and diabetes. Diabet Care. 2008, 31 (6): 1155-1159. 10.2337/dc08-0032.View ArticleGoogle Scholar
- Redekop WK, Koopmanschap MA, Rutten GE, Wolffenbuttel BH, Stolk RP, Niessen LW: Resource consumption and costs in Dutch patients with type 2 diabetes mellitus. Results from 29 general practices. Diabet Med. 2002, 19 (3): 246-253. 10.1046/j.1464-5491.2002.00654.x.View ArticlePubMedGoogle Scholar
- Schouten LM, Niessen LW, van de Pas JW, Grol RP, Hulscher ME: Cost-effectiveness of a quality improvement collaborative focusing on patients with diabetes. Med Care. 2010, 48 (10): 884-891. 10.1097/MLR.0b013e3181eb318f.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/12/46/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.